-
Tucatinib, sold
under the
brand name Tukysa, is an
anticancer medication used for the
treatment of HER2-positive
breast cancer. It is a
small molecule...
- -
selective MEK
inhibitor -
Approved 2018,
acquired by
Pfizer TUKYSA (
Tucatinib) - HER2
inhibitor -
Approved 2020,
owned by
Seagen (Seattle Genetics)...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
- also
prolong survival, as can HER2
inhibitors lapatinib, neratinib, or
tucatinib.
Certain therapies are
targeted at
those whose tumors have particular...
-
Osimertinib Rociletinib Vandetanib) HER1/EGFR and HER2/neu
Lapatinib Neratinib Tucatinib RTK
class III: C-kit and
PDGFR (Avapritinib
Axitinib Masitinib Pazopanib...
-
emtansine Kinase inhibitors:
Afatinib Lapatinib Mubritinib Neratinib Tucatinib ErbB3/HER3 Agonists:
Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))...
